InvestorsHub Logo
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Monday, 09/24/2018 10:01:35 AM

Monday, September 24, 2018 10:01:35 AM

Post# of 751
GILD will launch Harvoni/Epclusa authorized generics for US market in Jan 2019; list price of these AGs will be $24K for 8 weeks—equivalent to the existing after-rebate net price of branded Harvoni/Epclusa, and close to the list prices of Mavyret and Zepatier:

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2368563

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News